Literature DB >> 3815900

Development of anti-polysaccharide antibodies in asplenic children.

L Hammarström, C I Smith.   

Abstract

Splenectomized patients are highly susceptible to infections with capsulated bacteria and an impaired response to vaccination with bacterial polysaccharides has frequently been observed in these individuals. Based partly on experimental animal data, an important role for the spleen in the production of specific anti-carbohydrate antibodies, i.e. mostly IgG2 in normal adults, has been suggested. We therefore determined the immunoglobulin class and subclass pattern of serum antibodies from asplenic patients against protein and carbohydrate antigens. Normal levels of total serum IgM, IgG2 and specific IgM and IgG2 anti-polysaccharide antibodies were observed, suggesting only a minor role for the spleen in determining the antibody repertoire. The data imply that the impaired phagocytic capacity and/or the inability to mount a sufficiently rapid antibody response are the main factors underlying the increased susceptibility to bacterial infections noted in these patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3815900      PMCID: PMC1542520     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease.

Authors:  G R Siber; S A Weitzman; A C Aisenberg; H J Weinstein; G Schiffman
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

2.  Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy.

Authors:  A J Ammann; J Addiego; D W Wara; B Lubin; W B Smith; W C Mentzer
Journal:  N Engl J Med       Date:  1977-10-27       Impact factor: 91.245

3.  Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine.

Authors:  S W Hosea; C G Burch; E J Brown; R A Berg; M M Frank
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

4.  IgG subclass levels in infancy and childhood.

Authors:  V A Oxelius
Journal:  Acta Paediatr Scand       Date:  1979-01

5.  Response of patients with Hodgkin's disease to pneumococcal vaccine.

Authors:  D R Minor; G Schiffman; L S McIntosh
Journal:  Ann Intern Med       Date:  1979-06       Impact factor: 25.391

6.  Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae.

Authors:  D E Briles; M Nahm; K Schroer; J Davie; P Baker; J Kearney; R Barletta
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

7.  Antibody response to vaccination with pneumococcal capsular polysaccharides in splenectomized children.

Authors:  F K Pedersen; J Henrichsen; G Schiffman
Journal:  Acta Paediatr Scand       Date:  1982-05

8.  Cytoplasmic immunofluorescence of bone marrow plasma cells producing immunoglobulins of the four IgG subclasses.

Authors:  A Morell; F Skvaril; W Hijmans; R Scherz
Journal:  J Immunol       Date:  1975-08       Impact factor: 5.422

9.  Immune response after splenectomy.

Authors:  J L Sullivan; H D Ochs; G Schiffman; M R Hammerschlag; J Miser; E Vichinsky; R J Wedgwood
Journal:  Lancet       Date:  1978-01-28       Impact factor: 79.321

10.  Class and subclass anti-pneumococcal antibody responses in splenectomized patients.

Authors:  S Oldfield; S Jenkins; H Yeoman; D Gray; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

View more
  2 in total

Review 1.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

2.  Class- and subclass-specific pneumococcal antibody levels and response to immunization after bone marrow transplantation.

Authors:  J E Lortan; A Vellodi; E S Jurges; K Hugh-Jones
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.